JPMorgan Chase & Co. Reiterates Overweight Rating for Smith & Nephew (LON:SN)

JPMorgan Chase & Co. reiterated their overweight rating on shares of Smith & Nephew (LON:SN) in a report published on Thursday morning, MarketBeat Ratings reports. JPMorgan Chase & Co. currently has a GBX 1,300 ($16.18) target price on the stock.

A number of other equities analysts have also commented on the company. Royal Bank of Canada reaffirmed an outperform rating and issued a GBX 1,500 ($18.67) price objective on shares of Smith & Nephew in a research note on Friday, April 5th. Barclays reaffirmed an equal weight rating and issued a GBX 1,150 ($14.32) price objective on shares of Smith & Nephew in a research note on Friday, February 9th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of Moderate Buy and an average target price of GBX 1,362.50 ($16.96).

Smith & Nephew Price Performance

Smith & Nephew stock opened at GBX 966.80 ($12.04) on Thursday. The stock’s 50 day moving average is GBX 1,048.36 and its 200 day moving average is GBX 1,034.10. The company has a debt-to-equity ratio of 59.11, a current ratio of 1.77 and a quick ratio of 0.84. The firm has a market cap of £8.45 billion, a P/E ratio of 4,000.83, a P/E/G ratio of 0.46 and a beta of 0.51. Smith & Nephew has a one year low of GBX 887 ($11.04) and a one year high of GBX 1,316.75 ($16.39).

Smith & Nephew Increases Dividend

The firm also recently announced a dividend, which will be paid on Wednesday, May 22nd. Shareholders of record on Thursday, March 28th will be issued a $0.23 dividend. This is an increase from Smith & Nephew’s previous dividend of $0.14. This represents a yield of 1.62%. The ex-dividend date is Thursday, March 28th. Smith & Nephew’s payout ratio is presently 12,500.00%.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.